IN.PACT™ AV drug-coated balloon (DCB)
It’s clear.
IN.PACT™ AV DCB is the proactive arteriovenous (AV) maintenance treatment option for end-stage kidney disease (ESKD) patients.
The choice is clear.
IN.PACT™ AV drug-coated balloon is the proactive AV maintenance treatment option that offers superior performance compared to PTA,1 fewer reinterventions,2 and a clear path for the dialysis lifeline.
Extend time between interventions.
AV access maintenance trials — target lesion primary patency†
IN.PACT™ AV DCB can extend the time between interventions by ~14.7 months1 — more than 5× longer than Lutonix™* DCB.3
† Primary patency endpoints are defined differently; results are from different studies and may vary in a head-to-head comparison; charts are for illustration purposes only.
Risks may include: pain; hemorrhage; arterial or venous aneurysm/thrombosis, dissection, infection, perforation, or rupture; loss of permanent access; allergic/immunologic reaction; and death.
First and only DCB with superior, sustained results at 36 months1,3
Results from separate trials comparing drug-coated balloons to standard PTA for AV fistula maintenance
Target lesion primary patency at 36 months†
IN.PACT™ AV DCB‡,1
Access circuit primary patency at 36 months†
IN.PACT™ AV DCB§,1
No statistical difference in all-cause mortality between PTA and IN.PACT™ AV DCB at 36 months1
Target lesion primary patency at 24 months†
Lutonix™* DCB◊,3
Access circuit primary patency at 24 months†
Lutonix™* DCB¶,3,8
† Primary patency endpoints are defined differently; results are from different studies and may vary in a head-to-head comparison; charts are for illustration purposes only.
Significantly reduces access circuit thrombosis1
56% fewer reinterventions.2 More of what matters.
Patients treated with IN.PACT™ AV DCB demonstrate a reduced need for reinterventions compared to PTA. This can help enable longer periods of uninterrupted dialysis and could keep patients out of the hospital longer, which may positively impact patients’ lives.2
Watch Dianne and Dominic‘s stories to see how this proactive maintenance treatment helped decrease the number of maintenance procedures they needed, allowing them to focus on the things they love most.
Proactive approach
The IN.PACT™ AV DCB can slow the progression of fistula stenosis. A functioning fistula can eliminate the need for catheter-based dialysis, decreasing risk of infection and all-cause mortality.2
IN.PACT™ AV DCB minimizes the potential post-treatment limitations of stents, leaving a clear path for the dialysis lifeline.